DTech Liquidating

DTech Liquidating Pre-Tax Margin

Delisted

The Pre-Tax Profit Margin of DTech Liquidating (DMTKQ) as of Oct 18, 2026 is -659.57 %. In the previous year, Pre-Tax Profit Margin was -803.58 % — a change of -17.92% (higher).

Pre-Tax Margin

-659.57 %

YoY

-17.92%

Last updated:

Pre-Tax Profit Margin of DTech Liquidating is 2023 -659.57 % . Pre-Tax Profit Margin of DTech Liquidating was 2022 -803.58 % . It decreases by -17.92% higher compared to the previous year.

The DTech Liquidating Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2019
-586.01 USD
Jan 1, 2020
-619.35 USD
Jan 1, 2021
-661.66 USD
Jan 1, 2022
-803.58 USD
Jan 1, 2023
-659.57 USD
The DTech Liquidating Pre-Tax Margin history
YEARPre-Tax MarginYoY
-659.57 %-17.92%
-803.58 %+21.45%
-661.66 %+6.83%
-619.35 %+5.69%
-586.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DTech Liquidating Inc, trading under the ticker DMTKQ with ISIN US24984K1051, is a U.S.-based company headquartered in San Diego. It operates within the Health Care sector, specifically in the Biotechnology industry. The company has 278 employees and completed its IPO on June 20, 2017. DTech Liquidating Inc is focused on the development and sale of products for the diagnosis and treatment of skin diseases. Its technology involves non-invasive genomics tests designed to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. The company utilizes a method that detects genomic markers associated with melanoma through non-invasive skin sample collection, aiming to identify higher-risk lesions at early stages to rule out melanoma. The DermTech Melanoma Test, also known as the DMT or Pigmented Lesion Assay (PLA), is marketed for the clinical assessment of pigmented skin lesions that may indicate melanoma. The company's products are intended to address unmet needs in the diagnostic process for pigmented skin lesions, commonly referred to as moles. DTech Liquidating Inc's operations are centered around providing innovative solutions for skin disease diagnosis and management, leveraging non-invasive genomic analysis techniques. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Pre-Tax Profit Margin of DTech Liquidating is -659.57 % in 2023.

Pre-Tax Profit Margin of DTech Liquidating changed from -803.58 % to -659.57 %, representing a -17.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — DTech Liquidating

All Key Metrics — DTech Liquidating